Retatrutide (Triple agonist: GIP, GLP-1, and Glucagon)

Overview

RETATRUTIDE is a triple receptor agonist that acts on GLP-1, GIP, and glucagon receptors. It is used in the treatment of type 2 diabetes and obesity management. RETATRUTIDE is produced in vials of 10 mg, containing the active peptide with excipients.

Retatrutide (Triple agonist: GIP, GLP-1, and Glucagon) Mechanism of Action

RETATRUTIDE binds to three receptors: GLP-1, GIP, and glucagon. This triple action increases insulin secretion, reduces glucagon release, slows gastric emptying, suppresses appetite, and enhances energy expenditure. The GLP-1 and GIP pathways improve glucose control and satiety, while the glucagon pathway increases metabolic rate and fat oxidation. The combined effect is stronger blood sugar regulation, reduced food intake, and accelerated fat loss compared to single receptor agonists.

Retatrutide (Triple agonist: GIP, GLP-1, and Glucagon) Dosage

Administer as indicated by a medical professional.

Retatrutide (Triple agonist: GIP, GLP-1, and Glucagon) Side Effects

Nausea, vomiting, diarrhea, abdominal discomfort, hypoglycemia, injection site reactions, and in rare cases, gallbladder or pancreatic complications.

Retatrutide (Triple agonist: GIP, GLP-1, and Glucagon) Interactions

Other antidiabetic medications, insulin, and beta-blockers may alter or enhance its effects.